Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Gottenberg, Jacques Eric ^a   Seror, Raphaèle ^b   Miceli Richard, Corinne ^b   Benessiano, Joelle ^c   Devauchelle Pensec, Valerie ^d   Dieude, Philippe ^c   Dubost, Jean Jacques ^e   Fauchais, Anne Laure ^f   Goeb, Vincent ^g   Hachulla, Eric ^h   Hatron, Pierre Yves ^h   Larroche, Claire ⁱ   Le Guern, Véronique ^j   Morel, Jacques ^k   Perdriger, Aleth ^l   Puéchal, Xavier ^j   Rist, Stephanie ^m   Saraux, Alain ^d   Sene, Damien ⁿ   Sibilia, Jean ^a   Vittecoq, Olivier ^o   Nocturne, Gaétane ^b   Ravaud, Philippe ^p   Mariette, Xavier ^b   more..

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

^e ISIMA   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j Rheumatology Rennes University Hospital ^*  (France)

^k MONTPELLIER UNIVERSITY HOSPITAL   (France)

^l RENNES UNIVERSITY HOSPITAL   (France)

^m Rheumatology Orléans Hospital   (France)

ⁿ HÔPITAL LARIBOISIÈRE   (France)

^o ROUEN UNIVERSITY HOSPITAL   (France)

^p HÔTEL DIEU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; CORTICOSTEROID DERIVATIVE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN FREE LIGHT CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; EULAR SJOGREN SYNDROME DISEASE ACTIVITY INDEX; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIMARY SJOEGREN SYNDROME; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SJOEGREN SYNDROME; SYSTEMIC DISEASE;

AGED; B-CELL ACTIVATING FACTOR; BETA 2-MICROGLOBULIN; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LYMPHOMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84878118827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059868     Document Type: Article

References (35)

1. Fox RI, (2005) Sjögren's syndrome. Lancet. 23-29 366: 321-31.
2. Mariette X, Gottenberg JE, (2010) Pathogenesis of Sjögren's syndrome and therapeutic consequences. Curr Opin Rheumatol 22: 471-7.
3. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, et al. (2006) Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 65: 796-803.
4. Ioannidis JP, Vassiliou VA, Moutsopoulos HM, (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum. 46: 741-7.
5. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, et al. (1978) Increased risk of lymphoma in siccasyndrome.Ann Intern Med. 89: 888-92.
6. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, et al. (2011) EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010; 69: 1103-9. Erratum in: Ann Rheum Dis. 70: 880.
7. Mackay F, Groom JR, Tangye SG, (2007) An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol. 19: 406-13.
8. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K, (2005) Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol. 25: 189-201.
9. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, et al. (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome.Ann Rheum Dis. 62: 168-71.
10. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, et al. (2008) B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand J Immunol. 67: 185-92.
11. Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, et al. (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 56: 1464-77.
12. Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, et al. (2007) Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis. 66: 790-7.
13. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, et al. (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood.15 104: 2247-53.
14. Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, et al. (2005) Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis. 64: 1050.
15. Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, et al. (2007) Serum immunoglobulin free light chainassessment in rheumatoid arthritis and primary Sjogren'ssyndrome. Ann Rheum Dis. 66: 23-7.
16. Michalski JP, Daniels TE, Talal N, Grey HM, (1975) Beta2 microglobulin and lymphocytic infiltration in Sjögren's syndrome. N Engl J Med. 293: 1228-31.
17. Moutsopoulos HM, Steinberg AD, Fauci AS, Lane HC, Papadopoulos NM, (1983) High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome. J Immunol (130):: 2663-5.
18. Pertovaara M, Korpela M, (2011) Serum beta2-microglobulin correlates with the new ESSDAI in patients with Sjögren's syndrome. Ann Rheum Dis 70: 2236-2237.
19. Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, et al. (2012) BLyS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology August epub ahead of print.
20. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, et al. (2011) EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): developmentof a consensus patient index for primary Sjogren'ssyndrome. Ann Rheum Dis (70):: 968-72.
21. Smith DK, Neal JJ, Holmberg SD, (1993) Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection: an investigation of cases in the United States. N Engl J Med. 328: 373-379.
22. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, et al. (2006) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54: 723-32.
23. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, et al. (2007) Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 66: 700-3.
24. Voulgarelis M, Moutsopoulos HM, (2008) Mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: risks, management, and prognosis. Rheum Dis Clin North Am. 34: 921-33.
25. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM, (1996) Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum. 39: 767-72.
26. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, et al. (2006) Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 65: 796-803.
27. Gottenberg JE, Mariette X, (2012) Primary Sjogren's Syndrome: Time for Prospective Cohorts. Curr Pharm Biotechnol. 1 13(10): 2022-5.
28. Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, et al. (2003) In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response.Arthritis Rheum. 48: 2240-5.
29. Candon S, Gottenberg JE, Bengoufa D, Chatenoud L, Mariette X, (2009) Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity. Ann Rheum Dis. 68: 1208-12.
30. Gottenberg JE, Sellam J, Ittah M, Lavie F, Proust A, et al. (2006) No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome. Arthritis Res Ther. 8: R30.
31. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M, (2008) Polymorphism in the 5′ regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in pirmary Sjögren's syndrome. Rheumatology 47: 1311-1316.
32. Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, et al. (2011) Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum 63: 1446-51.
33. Novak AJ, Slager SL, Fredericksen ZS, Wang AH, Manske MM, et al. (2009) Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res. 15 69: 4217-24.
34. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, et al. (2006) Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol. 20 24: 983-7.
35. Emmerich F, Bal G, Barakat A, Milz J, Mühle C, et al. (2007) High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol (136):: 309-1.